Paul Golumbek

TL;DR: The results have important implications for the clinical use of genetically modified tumor cells as therapeutic cancer vaccines and the levels of anti-tumor immunity reported previously in cytokine gene transfer studies involving live, transduced cells could be achieved through the use of irradiated cells alone.

TL;DR: MHC class I-restricted antigens are efficiently transferred in vivo to bone marrow-derived antigen-presenting cells, which suggests that human leukocyte antigen matching may be less critical in the application of tumor vaccines than previously thought.

TL;DR: These findings demonstrate that the failure of an effective antitumor immune response may be primarily due to a helper arm deficiency of the immune system rather than a paucity of tumor-specific cytotoxic effector cells and outline a novel strategy for augmenting tumor immunity.

TL;DR: Established parental tumors could be cured by the systemic immune response generated by injection of the genetically engineered tumors by providing a rationale for the use of lymphokine gene-transfected tumor cells as a modality for cancer therapy.

TL;DR: This work explored an alternate approach to generating sustained release of cytokines local to the tumor cells and resulted in systemic anti-tumor immune responses comparable to granulocyte-macrophage colony-stimulating factor gene transduced tumor vaccines.